Genetics and Environment iNtersection In the ALS-FTD Spectrum: an Italian Twins Cohort studY With a Multi-Omics Approach
NCT ID: NCT06595212
Last Updated: 2025-02-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
45 participants
OBSERVATIONAL
2024-01-29
2026-01-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* How far does the genetic background explain the onset of ALS/FTD in discordant twins?
* Which environmental factors and events occurring in post-fetal life influence the onset or progression of this neurodegenerative condition? Participants with ALS and/or FTD with a monozygotic or dizygotic twin willing to contribute to this research will be followed up for two years by specialized Motor Neuron Disorders centers in Italy, donating biological specimen for -omic sciences analysis, and checking out if prodromal signs/symptoms of these two conditions will develop during time.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Needs of ALS Patients With C9orf72 Mutation and Their Caregivers
NCT07302321
Dysfunctions and Plasticity Mechanisms of Motor System Assessed by Cortico-cortical and Cortico-muscular Coherence Analysis in Amyotrophic Lateral Sclerosis
NCT01959373
Biomarker Research in Inherited Movement Disorders
NCT05034172
Study of Cognitive and Emotional Disorders in Amyotrophic Lateral Sclerosis
NCT01530438
Study of Biomorkers and Rehabilitation Strategies in Functional Motor Disorders (FMD)
NCT06328790
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* to disclose part of the heritability gap in monozygotic (MZ) discordant twins
* to assess the burden of epigenetic and transcriptomic differences between MZ discordant twins, uncovering which pathways are activated/inactivated in asymptomatic twins and may protect them from the neurodegenerative process
* to evaluate the effects of environment on the risk of developing ALS/FTD (discordant twins) and of developing different phenotypes of ALS (concordant twins). Exposure history will be related to quantification of pesticides, heavy metals and metalloids in biological samples.
* to investigate how lifetime environmental exposures affect microbiota composition and next metabolomics and immune profile
* to correlate biological signatures with clinical features and disease heterogeneity (onset, progression, survival) for discordant twins
* to correlate environmental factors exposure with biological factors as mentioned above (e.g.microbiota, immunological. factors)
* to acquire biological data over time to discriminate between changes related to disease pathogenesis and epiphenomena secondary to the disease advancement.
* to assess neurophysiological, neuropsychological and imaging signatures within the ALS-FTD spectrum of disease across discordant twins, in particular in the asymptomatic twin, in order to disclose potential presymptomatic subclinical traits. In concordant twins, the same extensive batteries will be used to evaluate whether disease progression proceeds at the same pace or affects similar or divergent neuroanatomical substrates.
Study population Being a national ALS-FTD twin cohort study, study population could include all Italian MZ and dizygotic (DZ) twins of whom at least one is affected by ALS or ALS-FTD and possibly their parents for trios studies. ALS/FTD twins will be invited from the referring neurologist to participate in the GENIALITY study and will be sent for screening and baseline visits to the nearest clinical center involved in this study, either Modena, Turin or Palermo.
Twin pairs will undergo a detailed interview, visit, clinical tests including neuropsychological testing (NPS), neuroimaging and neurophysiological studies, extensive environmental and exposure history, and blood, CSF (optional), skin, hair, saliva and stool collection.
ALS patients will be followed up by the centers with visits scheduled every 3-4 months as for clinical practice, while healthy twins will be asked to be followed with neurological evaluations every 6 months up to 24 months of the study duration.
Twins and parents (optional) will be asked to undergo a detailed interview, neurological examination, samples collection (parent-offspring trios studies) including blood sample, saliva and faeces una tantum.
Standard Operating Procedures (SOPs) for sampling, biobanking, clinical, and imaging studies will be shared by all the centers involved in the consortium. SOPs will include requirements for collection, analysis and storage of biological materials and guidelines concerning the shipping of the samples from one center to another, but also guideline concerning the patients' recruitment, informed consent collection, clinical scales, questionnaires administration. Furthermore, a battery of NPS tests will be shared with centers, as well as methods for neurophysiological assessment and requirements for imaging studies (brain MRI and PET).
This project will generate multi-omics parameters and correlated demographic and clinical data in ALS/FTD patients, their co-twins and possibly their parents. Data collected from interviewers, medical record review, and laboratory data, will be recorded in online case report forms.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
affected twins
multiomic profile to assess genetic and environmental risk factiors
Genomic, epigenetic, proteomic, microbiome, immunology, biomarker, metabolite, pesticide, metal, and metalloid investigations will be conducted. The twins will be followed longitudinally from a clinical perspective, with biological sample collections to assess discordance and identify early disease signatures in unaffected individuals.
unaffected twins
multiomic profile to assess genetic and environmental risk factiors
Genomic, epigenetic, proteomic, microbiome, immunology, biomarker, metabolite, pesticide, metal, and metalloid investigations will be conducted. The twins will be followed longitudinally from a clinical perspective, with biological sample collections to assess discordance and identify early disease signatures in unaffected individuals.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
multiomic profile to assess genetic and environmental risk factiors
Genomic, epigenetic, proteomic, microbiome, immunology, biomarker, metabolite, pesticide, metal, and metalloid investigations will be conducted. The twins will be followed longitudinally from a clinical perspective, with biological sample collections to assess discordance and identify early disease signatures in unaffected individuals.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presence of MZ or DZ twins in the family both willing to participate in the study and able to provide informed consent
* At least one twin is affected by ALS as defined by Gold Coast Criteria (Shefner et al., 2020) and/or by FTD as defined by Strong and colleagues (Strong et al., 2017)
* Subjects able and willing to comply with study procedures as per protocol
* Subjects able to understand, and capable of providing informed consent at screening visit before any protocol-specific procedures
Exclusion Criteria
* Unwillingness to donate biological samples collected at periphery (lumbar puncture excluded) for both twins
* Women who are pregnant or breastfeeding
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
A.O.U. Città della Salute e della Scienza - Molinette Hospital
OTHER
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
OTHER
University of Modena and Reggio Emilia
OTHER
Azienda Ospedaliero-Universitaria Careggi
OTHER
Azienda Ospedaliero-Universitaria di Modena
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
JESSICA MANDRIOLI
Prof
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Azienda Ospedaliero-Universitaria di Modena
Modena, Italy, Italy
Azienda Ospedaliero-Universitaria Policlinico P. Giaccone di Palermo
Palermo, Italy, Italy
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
Torino, Italy, Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PNRR-MAD-2022-12375798
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.